The oxfendazole pulse release bolus

A comparison of early and mid grazing season suppressive anthelmintic treatments for first year grazing calves and their effects on natural and experimental infection during the second year

A comparison was made of the efficacy and parasitological sequelae over 2 years, of continuous and intermittent periods of anthelmintic suppression applied both early and in the middle of the first grazing season of calves. Five groups of 15 calves grazing separate paddocks within the same field were allotted to one of the following treatment regimes during their first year at grass: Group 1, untreated controls; Group 2, treated with ivermectin injections at 3, 8 and 13 weeks after turnout; Group 3, treated with ivermectin injections at 10, 15 and 20 weeks after turnout; Group 4, treated with a morantel slow release intraruminal bolus at turnout; Group 5, treated with a morantel slow release bolus at 10 weeks after turnout. Five animals from each group were slaughtered at the end of both grazing seasons. Two months after the end of the second season the remaining five calves were challenged with an experimental infection of 250,000 third-stage larvae (L3) of both Ostertagia ostertagi and Cooperia oncophora. All treatment regimes protected the respective calves from parasitic gastroenteritis. Over the 2 year observation period Groups 2 and 4 showed significantly better weight gain than other groups, and at the end of the first season, they were found to harbour significantly fewer O. ostertagi in the early fourth stage of development. During Year 1, Groups 2 and 3 excreted much lower percentages of Ostertagia spp. eggs than other groups. In Year 2, Group 2 excreted a higher percentage of Ostertagia spp. eggs although the total egg output was approximately half that of Group 1 during the same period. The results showed that the effects of anthelmintic suppression on egg output of different nematode species was affected by the activity of the anthelmintic used.

Relationship between pharmacological properties and clinical efficacy of ruminant anthelmintics

The purpose of this review article is to establish a relationship between pharmacological properties and clinical efficacy of the most widely used broad-spectrum veterinary anthelmintics. The impact of drug pharmacokinetics/pharmacodynamics on anthelmintic efficacy and resistance is discussed. We review the clinical pharmacokinetics of the currently available anthelmintics used in livestock-imidazothiazoles, tetrahydropyrimidines, benzimidazoles/pro-benzimidazoles, salicylanilides (closantel) and avermectin-type compounds. Understanding the pharmacokinetic and metabolic behaviour of broad-spectrum anthelmintics in the host, and factors modulating that behaviour, is highly important for maximizing anthelmintic utility and efficacy.

Bioavailability and bioequivalence of veterinary drug dosage forms, with particular reference to horses: an overview

The route of administration and formulation of the dosage form affect the bioavailability (rate and extent of absorption) of a drug and may thereby influence the intensity and duration of the pharmacological effect. Location of injection site may affect the plasma concentration profile of drugs administered as aqueous suspensions or sustained release parenteral preparations (procaine penicillin G). When absorption influences the rate of elimination ('flip-flop' phenomenon), the apparent half-life of the drug will be increased (cefazolin sodium, i.m.; meclofenamic acid, p.o.). Absorption generally approximates a first-order process and either the absorption half-life or the mean absorption time (statistical moment term) will provide an estimate of the rate of absorption. The method of corresponding areas is the usual technique employed in estimating the extent of absorption (systemic availability). Inherent in this technique is the assumption that clearance of the drug remains unchanged. In horses, the time of feeding relative to oral dosing has been shown to affect systemic availability (rifampin, trimethoprim) and pattern of absorption (phenylbutazone). Oral paste formulations (trimethoprim-sulphadiazine, ivermectin) are convenient to administer, allow precision in dosage compared with powders or granules added to feed, and could provide sustained release. Assessment of bioequivalence is based on relative bioavailability, using a reference dosage form, together with a measure of the uncertainty (variance) of the estimate. Bioequivalence relies on the concept that preparations of a drug which provide essentially equivalent plasma concentration profiles should produce the same therapeutic effect.

Chemoprophylaxis and immunity to parasitic bronchitis in cattle--a field experiment comparing topical ivermectin and an oxfendazole intraruminal device

Seeder calves infected with Dictyocaulus viviparus were used to contaminate a field divided into three similar paddocks. Twenty-four autumn-born calves were allocated to three matched groups; one group was given topical ivermectin treatments (0.5 mg/kg) at 3, 8 and 13 weeks after turnout (Day 0); each member of a second group was given an oxfendazole pulse-release intraruminal device (OPRB) at turnout; while a third group was kept as untreated controls to monitor the natural epidemiological pattern of events. Severe pasteurella pneumonia exacerbated by lungworm infection occurred in the controls after Day 24. Two died and repeated doses of antibiotic and anthelmintic therapy were necessary to save the remainder. Clinical signs were much milder in the ivermectin and OPRB groups and resolved with only a single dose of antibiotic. The OPRB group excreted some lungworm larvae at this time, but none was detected in the faeces of the ivermectin group during the grazing season. At housing, five calves from each group and four lungworm-naive calves were challenged with D. viviparus larvae. The infection became patent in all challenge-control calves, but no larvae were passed by any of the trial animals. Post-mortem worm-counts revealed percentage takes for the challenge controls, trial controls, ivermectin and OPRB groups of 16.7, 0.01, 0.9 and 0.2, respectively. All trial groups had therefore developed a substantial immunity.

Delay in timing of the oxfendazole pulse release bolus in calves in The Netherlands

The efficacy of the oxfendazole pulse release bolus (OPRB) was tested in a grazing experiment at the University of Utrecht. Three groups of four OPRB-treated calves and one group of four untreated control calves were grazed on separate pastures between 18 May and 21 October 1987. Based on faecal egg counts for strongyle-type eggs and Nematodirus eggs, embryonation of Nematodirus eggs and faecal larval counts for lungworm, the first pulse of oxfendazole was released after 28 to 63 days, which was later than the period of approximately three weeks indicated by the manufacturer and others. As far as could be detected, the second to fifth pulses were not as delayed, but generally the three-week period was also exceeded. This delayed release of the pulse resulted in a build-up of pasture infectivity for gastrointestinal nematode larvae and lungworm larvae. Nevertheless, this did not result in clinical gastrointestinal helminthiasis and husk in the treated groups of calves, whereas severe husk and mild gastrointestinal helminthiasis were seen in the control group.